Phosphagenic's 14-year record surge
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Phosphagenics (POH) enjoyed its best one-day surge in over 14 years today after management finally delivered something shareholders could cheer about.
The biotech that is developing through-the-skin drug delivery solution announced an exciting Phase I trial result using its oxymorphone patch for pain treatment.
The stock rallied 47.6% to its highest level in eight months of 15.5 cents on the news, and the uplift comes on very strong volumes.
It’s been a tough year for shareholders with the company plagued by scandal after its former chief executive Esra Ogru and five others were alleged to have misappropriated $5.7 million from the company over the past eight years.
Phosphagenics is confident that it will be able to recover most of the funds and its acting chief executive, Harry Rosen, said Ogru is cooperating with the company on this front, although some of the other alleged co-conspirators who were not named by the company are proving more difficult to deal with.
Rosen also confirmed today that the company is close to announcing a new chief executive and that he was pushing for a board renewal given the lax oversight.
The latest clinical result should also go some ways to reassure sceptics that Phosphagenics’ technology works. Fund managers that I have been speaking with over the years about Phosphagenics have voiced concern that the company’s technology had slim chances of success given that many have tried unsuccessfully to achieve a similar outcome in the past.
Phosphagenics is now looking to conduct a Phase II trial before looking for a large pharmaceutical company to partner to fund the final clinical trial.
The company is the best performing stock on the Uncapped 100 today.
Call 1300 880 160
Start a chat
Schedule a call
